To introduce new technology for the design of innovative intraocular lenses (iols) that fully restore natural peripheral vision for motion detection, significantly improving quality of life of yearly millions of cataract patients with an iol implant.
Development of aav5-gdnf gene technology platform for brain diseases, focusing in this project on proof of concept for huntington disease and multiple system atrophy.
Peptide administration for lung fibrosis treatment using formulation based on medusa technology. develop a sustained release formulation os p144 or p17, loquid or freeze-dried form, for subcutaneous administration route and carry on preclinical and clinical trials.
Invitrotek ltd. Sti. (Istanbul, turkey) and pronto diagnostics ltd. (Tel aviv, israel) will collaborate in developing an assay, based on the targeted next generation sequencing to detect mutations in all thalassemia cases.
Patented microcrystalized hydrophobic phtalocyanine liposomal drug form plus nayf4 (dopped by yb and er) nanoparticle drug form with matching lasers will be developed, converting 980 nm to 670 nm and enabling unlimited light penetration for infrared pdt curing tumors/metastases in any location.
The aim of the project is research, development and preparation technology of nanolayers with antibacterial, antifungal and antiviral effects and methods of application used in the field of veterinary.
The project is focused on the use and medical application of antisense oligonucleotides, which selectively target expression of the genes encoding enzymes for synthesis of polysaccharides within streptococci in order to inhibit the formation of biofilm.
The catiomerc project aims to develop 100% natural cationic bio-charges for industrial applications in the field of cosmetic as an alternative to conventional petrochemical surfactants. These bio-charges are from the alliance of a section of chitin and / or its derivatives and clay.
To develop a genetic screening panel and its bioinformatic analysis software in order to detect mutations associated with hypertrophic cardiomyopathy. Required experimental methods and analysis pipeline will be developed.
This project will utilize innovative peptide design technology, unique peptide synthesis and modification capabilities and specialized activity testing models for the generation of innovative toll-like receptor antagonists and agonists. These will be used as both, research tools and drug candidates.